Auris Medical Holding AG (NASDAQ:EARS)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $1.26, but opened at $0.82. Auris Medical shares last traded at $0.43, with a volume of 7845300 shares changing hands.

Separately, Zacks Investment Research downgraded Auris Medical from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th.

The company has a debt-to-equity ratio of 1.43, a quick ratio of 2.56 and a current ratio of 2.56.

A hedge fund recently bought a new stake in Auris Medical stock. Virtu KCG Holdings LLC bought a new stake in Auris Medical Holding AG (NASDAQ:EARS) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 141,507 shares of the biotechnology company’s stock, valued at approximately $101,000. Virtu KCG Holdings LLC owned 0.32% of Auris Medical at the end of the most recent reporting period. Institutional investors own 26.46% of the company’s stock.

WARNING: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.watchlistnews.com/auris-medical-ears-shares-gap-down-to-0-82/1733637.html.

Auris Medical Company Profile

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with Analyst Ratings Network's FREE daily email newsletter.